ABBV Profile
AbbVie Inc. is a global biopharmaceutical company focused on discovering, developing, manufacturing, and selling innovative pharmaceuticals. The company's portfolio includes several high-profile medications such as HUMIRA, an injectable therapy for autoimmune and intestinal Behcet's diseases; SKYRIZI for moderate to severe plaque psoriasis in adults; and RINVOQ, a JAK inhibitor for moderate to severe active rheumatoid arthritis. AbbVie also offers IMBRUVICA for chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL), VENCLEXTA, a BCL-2 inhibitor for CLL or SLL, and MAVYRET for chronic HCV genotype 1-6 infection.
In addition to its primary products, AbbVie provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid for hypothyroidism; and Linzess/Constella for irritable bowel syndrome with constipation and chronic idiopathic constipation. Other significant products include Lupron for advanced prostate cancer, endometriosis, and central precocious puberty, as well as Botox for therapeutic use. The company's diverse portfolio also features ORILISSA for moderate to severe endometriosis pain, Duopa and Duodopa for Parkinson's disease, Lumigan/Ganfort for elevated intraocular pressure in open-angle glaucoma (OAG) or ocular hypertension, and Ubrelvy for migraines.
AbbVie is committed to advancing medical research through strategic collaborations, such as its partnership with Dragonfly Therapeutics, Inc. Founded in 2012 and headquartered in North Chicago, Illinois, AbbVie continues to drive innovation in healthcare, striving to address some of the world's most pressing health challenges through its extensive and growing range of pharmaceutical products.
|
